Winners of the 21st Pfizer Medical Awards announced
The winners of the 21st Pfizer Medical Awards, sponsored by Pfizer Pharmaceutical Korea and hosted by the Korean Academy of Medical Sciences, were announced on the 26th. The awards recognize excellence in the fields of basic medicine, clinical medicine, and translational medicine.
Basic Medicine Award
- Winner: Professor Ji Heon-young
- Affiliation: Department of Pharmacology, Yonsei University College of Medicine
- Achievement: Professor Ji’s groundbreaking research on cancer has established a new paradigm in understanding cancer metastasis. His research paper was published in the prestigious journal ‘Molecular Cancer’.
Clinical Medicine Award
- Winner: Professor Park Deok-woo
- Affiliation: Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine
- Achievement: Professor Park’s large-scale clinical study challenged the conventional practice of regular stress tests after coronary stent surgery for high-risk patients. His findings, published in the renowned ‘New England Journal of Medicine (NEJM)’, will impact global guidelines for patient care.
Translational Medicine Award
- Winner: Professor Kim Nam-guk
- Affiliation: Department of Convergent Medicine, Asan Medical Center, Ulsan University College of Medicine
- Achievement: Professor Kim’s research on medical artificial intelligence has introduced a new diagnostic system that can accurately detect various diseases in emergency patients. His groundbreaking work was published in the esteemed journal ‘Nature Communications’.
The winners will be honored at an award ceremony on November 1, where they will receive a prize of 50 million won and a plaque in recognition of their outstanding contributions to the field of medicine. The Pfizer Medical Awards continue to drive innovation and excellence in the medical community, contributing to the advancement of medical science on a global scale.
Director Wang Gyu-chang of the Korean Academy of Medical Sciences expressed his admiration for the award recipients, acknowledging that their research has not only improved the domestic medical landscape but also provided solutions to global challenges. CEO Dong-wook Oh of Pfizer Pharmaceuticals Korea emphasized the company’s commitment to supporting valuable research activities and elevating the standard of Korean medicine.
(From left in photo) Basic Medicine Award winner Professor Ji Heon-young of the Department of Pharmacology, Yonsei University College of Medicine, Clinical Medicine Award winner Professor Park Deok-woo, Department of Internal Medicine, Asan Medical Center, Univ. Ulsan College of Medicine, and Translational Medicine Award winner Professor Kim Nam-guk, Department of Convergence Medicine, Asan Medical Center, Ulsan University College of Medicine / Photo = Pfizer Korea Limitations
Korean Academy of Medical SciencesHosted by (Director Wang Gyu-chang) Pfizer Pharmaceutical KoreaThe winners of the ’21st Pfizer Medical Awards’ sponsored by (CEO Dong-wook Oh) were announced on the 26th.
This year’s Basic Medicine Award went to Professor Ji Heon-young of the Department of Pharmacology, Yonsei University College of Medicine, the Clinical Medicine Award went to Professor Park Deok-woo, Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine , and the Translational Medicine Award went to Professor Kim Nam-guk, Department of Convergent Medicine, Asan Medical Center, Ulsan University College of Medicine.
Pfizer Medicine Award(Pfizer Medical Research Award) is a pure medicine award established in 1999, which is the 30th anniversary of the establishment of Pfizer Pharmaceuticals Korea, to support the development of the domestic medical community and fulfill responsibility as a corporate citizen. Each year, the best papers are selected by evaluating the excellence, creativity, scientificity, and contribution of individual papers published within two years of the current year in three categories: basic medicine, clinical medicine, and translational medicine.
A Pfizer official said, “The Pfizer Medical Prize, which has discovered and supported a total of 52 medical scientists by selecting the 21st winners, gains more authority every year by encouraging and supporting a wide range of research by domestic medical scientists, from basic research to practical medical research “It is recognized for its value in medical science,” he explained.
According to the company, Professor Ji Heon-young, winner of the Basic Medicine Award, was the first to confirm the Adherent-to-Resistance Transition (AST) pattern and identify the role of cell adhesion regulators in the formation of circulating cancer cells and cancer metastasis. We established a paradigm that differs from the Epithelial-to-Mesenchymal Transition (EMT) hypothesis, which explains the phenomenon of reprogramming between existing epithelial and mesenchymal cell shapes, and key mediators such as transcription factors known to be specific to blood cells The arguments were confirmed.
Professor Ji won the Basic Medicine Award in recognition of his outstanding research achievements in contributing to solving difficult problems in the life sciences community and conducting research on cancer and sensory systems based on molecular cell biology and genetics. His research paper was published in academic global magazine in the field of cancer biology, it was published in ‘Molecular Cancer’.
Professor Deok-Woo Park, winner of the Clinical Medicine Award, conducted a large-scale clinical study comparing the incidence or mortality rates of major cardiac events according to whether regular stress tests were performed after coronary stent surgery in at-risk patients high As there was no significant difference between the two patient groups, regular tests were carried out uniformly. For the first time, clinical evidence was presented that there is no need to do it. Before the study, all high-risk patients undergoing coronary stent surgery underwent stress function tests such as exercise stress electrocardiography and drug stress echocardiography.
Professor Park was selected as the winner of the Clinical Medicine Award in recognition of his achievements in establishing the clinical basis for cardiovascular disease and raising the level of domestic cardiac medicine to a global level. The results of this study will be reflected in standard guidelines worldwide and are expected to have a direct impact on actual patient care. This study was published in the global medical journal ‘New England Journal of Medicine (NEJM)’.
Professor Namguk Kim, winner of the Translational Medicine Award, said the possibility of a triage system that uses a deep learning model as an anomaly detection method to find diseases by learning CT brain data of normal people instead of the commonly used method of learning specific confirmed diseases. By applying the outlier detection method, various diseases in emergency patients could be detected more accurately, and reading time was also significantly shortened.
Professor Namguk Kim conducted medical artificial intelligence (AI) research to identify a diagnostic system that can be applied in emergency situations with many variables, and used domestic data to present an alternative to address unmet needs in clinical settings to treat patients through AI diagnosis. was selected as the winner of the Translational Medicine Award after being evaluated as having discovered a new method. The results of the research were published in the scientific journal Nature Communications.
Meanwhile, the award ceremony will be held at Yonsei University’s Baekyang-ro Plaza Hall Grand Ballroom on November 1 at 6 pm The winners will receive a prize of 50 million won and a plaque for each category.
Wang Gyu-chang, Director of the Korean National Academy of Medical Sciences, said, “All the studies selected for the 21st Pfizer Prize in Medicine are outstanding research achievements that have not only improved the domestic medical environment but also introduced solutions to difficult problems. that remained unmet needs globally,” adding, “Innovation in the medical field.” “These are studies that add to this and enable a leap forward,” he said.
He continued, “Through the Pfizer Medical Award, we will continue to discover and honor the contributions of domestic medical scientists who have contributed to raising the status of our country’s medical science to a world-class level, and encourage the will of medical scientists to carry out research so that it can be carried out research for the development of our country’s medical science is more active “I hope I can contribute to this,” he added.
Dong-wook Oh, CEO of Pfizer Pharmaceuticals Korea, said, “The Pfizer Medical Prize, which has been running for 21 years, is very meaningful as it discovers outstanding research achievements by medical scientists and supports valuable research activities that n help develop domestic medicine and improve the treatment environment for patients “I think deeply,” he said.
“Pfizer pursues ‘innovation that changes patients’ lives’ and works to create a healthier world through science,” he said. “Together with domestic medical scientists, we will further raise the standard of Korean medicine and rapidly expand medical possibilities . ” “We will continue with various activities to make this happen,” he emphasized.
#Professor #Heonyoung #Park #Deokwoo #Kim #Namguk #receive #21st #Pfizer #Medical #Prize
